Gesellschaft Fur Biotechnologische Forschung Mbh

Ciba-geigy Corporation

Helmholtz-zentrum Fur Infektionsforschung Gmbh

Helmholtz-zentrum Fuer Infektionsforschung Gmbh

Gesellschaft Fuer Biotechnologische Forschung Mbh (gbf)

Gesellschaft Fur Biotechnologische Forschung Gmbh

Bristol-myers Squibb Compnay

Universität Des Saarlandes

Universitat Bielefeld

Gerth, Klaus

Steinmetz, Heinrich

Hofle, Gerhard

Klaus Gerth

Heinrich Steinmetz

Hans Reichenbach

Rolf Jansen

Norbert Bedorf

Herbert Irschik

Brigitte Kunze

Wolfram Trowitzsch-Kienast

Gerhard Hoefle

Florenz Sasse

Gerhard Hofle

Rolf Wolfgang Hartmann

Rolf Müller

Andreas Kirschning

Jennifer Herrmann

Kathrin Mohr

Mostafa Hamed

Edgar Forche

Franziska Gille

Ritesh Raju

Walid A M Elgaher

Maria Moreno

Sascha Baumann

Liang Liang Wang

Brian L Davis

Alfred Pühler

Johannes P Pachlatko

Hermann Augustiniak

Dietmar Schomburg

Victor Wray

Stephan Hüttel

Gerhard H Ofle

Ingo Hardt

Walid A Elgaher

Daniel A Benigni

Stephan Huettel

Mark Mascari

Stephan Huttel

Gregory Stein

Thomas P Tully

Walid A M Elhaher

Rolf MÜLLER

Susanne Schneiker

Lena Perlova

The present invention provides cystobactamides of formula (I): R&#x2014;Ar-L-Ar-L-Ar-L-Ar-L-Ar&#x2014;Rand the use thereof for the treatment or prophylaxis of bacterial infections.

Crystobactamides

The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections.R&#x2014;Ar-L-Ar-L-Ar-L-Ar-L-Ar&#x2014;R&#x2003;&#x2003;(I):

Cystobactamides

The present invention provides a method for the treatment or prophylaxis of bacterial infections by administering to a subject in need thereof an effective amount of a compound of formula. 

The present invention relates to epothilones C, D, E, and F, their preparation and their use for the production of therapeutic compositions and compositions for plant protection.

Epothilones C, D, E, and F, preparation and compositions

The invention concerns compounds which can be obtained by fermenting DSM 6773, especially epothilones A1, A2, A8, A9, B10, C1, C2, C3, C4, C5, C6, C7, C8, C9, D1, D2, D5, G1, G2, H1, H2, I1, I2, I3, I4, I5, I6 and K and trans-epothilones C1 and C2.

Epothilone side components

The invention relates to compounds which are obtained by fermenting DSM 6773, especially epothilones A1, A2, A8, A9, B10, C1, C2, C3, C4, C5, C6, C7, C8, C9, D1, D2, D5, G1, G2, H1, H2, I1, I2, I3, I4, I5, I6 and K and trans-epothilones C1 and C2.

Epothilone minor constituents

The invention relates to compounds of the following general formula I ##STR1## especially the compound of formula Ia referred to as thiangazole ##STR2## their pharmaceutically acceptable acid addition salts, processes for their preparation and therapeutic compositions and compositions that can be used in crop-protection.

Thiangazole, its preparation, compositions and use thereof

The invention relates to cyclic antibiotics of formula ##STR1## wherein the prefix R represents that the substituents on the adjacent carbon atom are in the R configuration; the prefix S represents that the substituents on the adjacent carbon atom are in the S configuration;

Macrocyclic antibodies

The invention relates to novel polycyclic alkaloids of formula ##STR1## in which R.sup.1 represents hydrogen or hydroxy, R.sup.2 represents hydrogen or acyl and A and B, independently of one another, each represents C.dbd.O or C--OH, and wherein the dashed line represents a C.dbd.C double bond at the position of the middle bond when A or B represents C.dbd.O, or at the position of the two outer bonds when A or B represents C--OH, a process for the manufacture of these compounds by fermentation of a novel microorganism of the species Myxococcus xanthus, the novel microorganism itself, pharmacetical preparations that contain the novel compounds, and the use of the novel compounds as antibiotics and as tumour-inhibiting agents and for the manufacture of pharmaceutical preparations.

Antibiotics from myxococcus

The invention relates to cyclic antibiotics of formula ##STR1## wherein the prefix R represents that the substituents on the adjacent carbon atom are in the R configuration; the prefix S represents that the substituents on the adjacent carbon atom are in the S configuration; R.sub.1 is hydrogen or hydroxy and R.sub.2 is hydroxy or .beta.-glucopyranosyloxy, and to the hydrates and salts thereof, especially pharmaceutically acceptable salts. The compounds of formula I are prepared by fermentation using the strain So ce 12 (NCIB 12134) of the species Sorangium celulosum and are effective antiobiotics.

Macrocyclic antibiotics

Growing community of inventors

Braunschweig, Germany

Klaus Gerth